Indaptus Therapeutics(INDP) - 2025 Q3 - Quarterly Results

Exhibit 99.1 Indaptus Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update NEW YORK (November 12, 2025) - Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company"), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announces financial results for the third quarter ended September 30, 2025, and provides a corporate update. Jeffrey Meckler, Indaptus Therapeutics' Chief Executive Officer, comm ...